Login to Your Account

Peloton puts pedal to the metal, extends D round to $74.6M

By Marie Powers
News Editor

Tuesday, March 14, 2017

Peloton Therapeutics Inc. exercised an optional $22.2 million tranche of its series D round, closed in September 2016 at $52.4 million, to extend the runway for its HIF-2 alpha antagonists, which are targeting renal and other solid tumors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription